Oppenheimer Reiterates Outperform on Kala Bio, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Kala Pharmaceuticals (NASDAQ:KALA) and maintains a $15 price target.

April 01, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating and a $15 price target on Kala Pharmaceuticals.
The reiteration of an Outperform rating and a maintained price target of $15 by a reputable analyst like Francois Brisebois from Oppenheimer is likely to instill confidence among investors and could lead to a positive short-term impact on KALA's stock price. Analyst ratings, especially those that are positive, can influence market perception and investor sentiment towards a stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100